+39 02 610346.1 - info@newron.com

Success in CNS drug development

We are a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Our shares are listed on the SIX Swiss Exchange (NWRN).

Latest press releases

  • 29May
    Newron Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

  • 4May
    Newron Reports Top-Line Results from its STARS Study Evaluating Sarizotan in Patients with Rett Syndrome

     

  • 29Apr
    Newron Acknowledges Definitive Agreement Between US WorldMeds and Supernus Pharmaceuticals Regarding XADAGO® (safinamide)

  • 15Apr
    Newron Receives Third Tranche from Financing Agreement with European Investment Bank (EIB)

     

  • 31Mar
    Newron AGM Result and Clinical and Business Update

     

  • 11Mar
    Newron updates on STARS study FDA interaction

     

View All

Newron share price

Events

  • 11Aug
    2020 Wedbush PacGrow Healthcare Virtual Conference

    August 11-12, 2020

  • 14Sep
    H.C. Wainwright 22nd Annual Global Investment Conference

    September 14-15, 2020 - Virtual

  • 23Sep
    Investora Zürich 2020

    September 23-24, 2020 – Zürich-Stettbach, Switzerland

View Event Calendar